Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02529137 · ClinicalTrials.gov registry record
Pivotal Study for Validation of Philips Dx (PDx)
A clinical trial of Pathologic Processes, sponsored by Philips Digital & Computational Pathology.
- Completed
- Registry status
- 2,000
- Enrollment target
- 4
- Study locations
NCT02529137 is a study of Pathologic Processes that has completed, run by Philips Digital & Computational Pathology. The registered enrollment target is 2,000 participants, above the 741-participant average among 13 other Pathologic Processes trials with a reported enrollment target (170% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT02529137, a study of Pathologic Processes, has completed, sponsored by Philips Digital & Computational Pathology.
- COMPLETED
- Registry status
- 2,000 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objective of this study is to show safety and effectiveness of the PDx for In Vitro Diagnostic (IVD) use as an aid to the pathologist to view, review and diagnose digital images of surgical pathology slides.
Conditions Studied
Study Locations (4)
Maryland
- Shady Grove Adventist - Silver Spring
Ohio
- Cleveland Clinic - Cleveland
Texas
- Miraca Life Sciences - Irving
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02529137
The ClinicalTrials.gov registry entry for NCT02529137 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 741-participant average among 13 other Pathologic Processes trials with a reported enrollment target (170% higher). The listed sponsor is Philips Digital & Computational Pathology, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pathologic Processes appearing as the primary indexed condition, and to 0 interventions.
NCT02529137 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Maryland, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT02529137 about?
NCT02529137 is a clinical study titled "Pivotal Study for Validation of Philips Dx (PDx)". The primary objective of this study is to show safety and effectiveness of the PDx for In Vitro Diagnostic (IVD) use as an aid to the pathologist to view, review and diagnose digital images of surgical pathology slides.
What is the current status of trial NCT02529137?
This trial is currently completed. The enrollment target is 2,000 participants. The study started on 2015-07. Estimated completion is 2016-09.
What conditions does trial NCT02529137 study?
This clinical trial studies the following conditions: Pathologic Processes.
Who is sponsoring clinical trial NCT02529137?
This trial is sponsored by Philips Digital & Computational Pathology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02529137 being conducted?
This trial has 4 study locations across Maryland, Ohio, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pathologic Processes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
RECRUITING · NA
-
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
RECRUITING · NA
-
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 2
-
Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients
ACTIVE NOT RECRUITING · Phase 3
-
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
ACTIVE NOT RECRUITING · Phase 2
-
Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.